Rivian faces significant challenges in 2023, including a looming 25% tariff on key EV components sourced from South Korea and China. Delivery targets have been cut, with expectations slashed to 37,000 units by 2025 due to financial and logistical hurdles. Bernstein analysts

Baker Hughes is a stable investment choice amidst speculative “story stocks.” The company has shown impressive growth, with EPS increasing by 56% over three years. Strong performance is backed by robust operational metrics, such as steady EBIT margins and a 9.1% revenue

Institutional investors control 66% of Bank of America, significantly influencing share prices and boardroom decisions. Key institutional stakeholders like Berkshire Hathaway, The Vanguard Group, and BlackRock hold 8.9%, 8.7%, and 6.9% stakes, respectively. The top 25 shareholders combined hold 49% of the

Institutional investors control a significant 56% of First Foundation Inc. (NYSE:FFWM), heavily influencing its future trajectory and stock valuation. Eight key investors hold 53% of the company’s equity, with hedge funds possessing 28%, highlighting their strategic interest. Canyon Capital Advisors LLC alone

In March 2025, the Nasdaq-100 index dropped a significant 7.6%, but Strategy Inc. and Electronic Arts managed impressive gains. Strategy Inc. achieved a 12.9% rise by investing heavily in Bitcoin, holding $35.6 billion in reserves, and raising $711 million through preferred stock

Diabetic neuropathy affects 28% to 55% of diabetes patients, with current treatments offering limited relief and side effects. MIRA Pharmaceuticals’ Ketamir-2, an oral ketamine analog, shows promise in reducing neuropathic pain in diabetic rats. Ketamir-2 avoids psychedelic effects, is non-addictive, and effectively

Dividend stocks, particularly 3M (NYSE:MMM), are resurging in popularity amid economic uncertainty. 3M’s stock increased nearly 5% in 2025, with a 49% return over the past year, showcasing a strong performance. CEO Bill Brown’s leadership has focused on revitalization, highlighted by the

Barfresh Food Group, Inc., a niche player in the American beverage industry, is poised for a major shift with its innovative frozen beverages. The company aims to transition from a $2.8 million loss in 2024 to a profit of $392,000 by 2026,

Boston Scientific Corporation’s fair value is estimated at US$80.33, while its current market price stands at US$93.67. The Discounted Cash Flow (DCF) model is used to evaluate the company’s valuation, with a projected per-share target of US$115 by optimistic analysts. Free cash